Questions to Ask Before HIPEC: Second Opinions, Expected Benefits and the Recovery Plan

The folder on the kitchen table is already half an inch thick. Scan reports, a pathology letter, a printout about something called cytoreductive surgery with HIPEC, and a sticky note from the surgeon’s office with the date of the next appointment. The person who owns that folder has one problem that the paperwork does not solve: they do not yet know what to ask.

That gap is normal. HIPEC is a long, uncommon operation that most people have never heard of until it is proposed for them or someone they love. The questions to ask before HIPEC are not obvious, because the procedure sits at the intersection of major surgery, chemotherapy and a still-evolving evidence base. Some of those questions have firm answers. Others have honest ones, which is different.

This explainer is built around the conversation you will have with your treating team. It covers what happens in the operating room, who is usually offered the procedure and who is asked to wait, where the evidence is strong and where it is contested, and what the weeks afterward tend to look like. Every decision stays with your clinicians. The goal here is to help you walk into that room prepared.

What actually happens during HIPEC, step by step

HIPEC stands for hyperthermic intraperitoneal chemotherapy: chemotherapy that is warmed above body temperature and circulated through the abdominal cavity while you are still on the operating table. It is almost never a stand-alone treatment. In practice it is the final phase of cytoreductive surgery, an operation whose aim is to remove every visible tumor deposit from the peritoneum, the thin membrane that lines the abdominal wall and wraps around the organs inside it.

The day unfolds in a fixed order. After general anesthesia, the surgeon opens the abdomen through a long midline incision and inspects every region, often recording a peritoneal cancer index, a score that tallies tumor size across thirteen areas of the abdomen. The resection follows: stripping involved peritoneum, and sometimes removing the omentum (the fatty apron over the intestines), part of the bowel, the spleen, the gallbladder, or the ovaries and uterus, depending on where disease sits.

Only then does the heated chemotherapy begin. Catheters are placed, the abdomen is temporarily closed or kept open under a protective cover, and a perfusion machine circulates the drug solution at roughly 41 to 43 °C (about 106 to 109 °F) for a period that typically runs 60 to 120 minutes, according to the Cleveland Clinic. The fluid is then drained, the cavity is rinsed, any bowel reconnections are completed, and the incision is closed.

The logic behind the heat is straightforward. Warmth makes cancer cells more vulnerable and helps the drug penetrate a few millimeters into tissue. The peritoneum also acts as a partial barrier, so a high local concentration can be delivered with less reaching the rest of the body than the same drug given intravenously. That shallow penetration is also the procedure’s limit: HIPEC is designed to treat microscopic residue, not visible lumps.

Why the surgery matters more than the heat

People tend to fixate on the chemotherapy bath because it sounds novel. Surgeons who do this work tend to fixate on something plainer: how much tumor is left behind when the resection ends. That quantity is captured in a completeness of cytoreduction score, usually written CC-0 through CC-3. A CC-0 result means no visible disease remains; CC-1 means only deposits smaller than a few millimeters are left; CC-2 and CC-3 mean larger residual tumor.

Because the heated drug reaches only a shallow depth, the whole strategy depends on getting to CC-0 or CC-1. When larger deposits remain, the perfusion washes over them without doing much, and the person has still absorbed the full risk of a long operation. This is why experienced teams spend most of the day on meticulous resection and treat HIPEC as the finishing step rather than the centerpiece.

It also explains why your first substantive question should be about the surgeon’s expectation of completeness. Ask what the imaging suggests about disease volume, whether a diagnostic laparoscopy (a short keyhole look inside the abdomen) is planned to check before committing to the full operation, and what the team will do if, once the abdomen is open, complete removal turns out not to be possible. Some teams close without performing HIPEC in that scenario; others proceed with a more limited plan. You are entitled to know the decision rule in advance.

Two further points follow from the same logic. Which organs might need to be removed depends on where disease sits, and you can ask for the realistic range, including the chance of a temporary or permanent stoma, an opening on the abdominal wall through which bowel contents pass into a bag. Second, the completeness score achieved on the day will shape your follow-up plan, so ask how it will be communicated to you afterward.

Who is HIPEC usually for, and when is HIPEC not recommended?

HIPEC is considered for cancers that have spread to, or arisen in, the peritoneal lining. The conditions most often discussed include pseudomyxoma peritonei (a slow-growing, mucus-producing tumor usually originating in the appendix), other appendiceal cancers, peritoneal mesothelioma, certain colorectal cancers with peritoneal spread, and some ovarian cancers at the time of interval surgery. The Cleveland Clinic lists these as the main indications, while noting that practice varies between teams and tumor types.

Being a candidate is less about the diagnosis label than about three practical conditions. The disease should be largely confined to the abdominal cavity, with little or no spread to the liver interior, lungs or bones. The volume of peritoneal disease should be low enough that complete removal is realistic. And the person needs to be fit enough to tolerate an operation that lasts most of a day and a recovery that lasts weeks.

When is HIPEC not recommended? The common reasons a team will decline or defer include widespread disease outside the peritoneum, extensive involvement of the small bowel or its blood supply (which cannot be removed without leaving too little intestine to live on), poor overall fitness or significant heart, lung or kidney disease, and tumor biology that tends to progress quickly despite aggressive local treatment. For colorectal cancer in particular, some teams have scaled back HIPEC following trial results discussed below, offering cytoreductive surgery alone instead.

Waiting is also a legitimate recommendation. A team may suggest systemic chemotherapy first to see how the disease responds, improving fitness through a prehabilitation program, or repeat imaging in a few months for a slow-growing tumor. If you are asked to wait, ask what specifically would change the decision, and how that will be measured.

Why is HIPEC controversial? What the trials actually show

The honest answer is that the evidence differs sharply by cancer type, and the strongest randomized data have produced mixed results. Understanding this helps you ask sharper questions.

For colorectal cancer, the Dutch trial published in 2003 compared cytoreductive surgery plus HIPEC against systemic chemotherapy of that era and reported longer survival in the surgical group, though the comparison arm used older drugs and the trial was small (Verwaal and colleagues, Journal of Clinical Oncology). The larger French PRODIGE 7 trial, published in 2021, took a different approach: everyone had complete cytoreductive surgery, and participants were randomized to receive oxaliplatin-based HIPEC or not. There was no statistically significant difference in overall survival between the groups, while serious complications at 60 days were more frequent in the HIPEC group, 26% versus 15% (Quenet and colleagues, Lancet Oncology). Many clinicians read this as evidence that the surgery, not the heated chemotherapy, is doing the work in colorectal disease.

For ovarian cancer the picture points the other way. A Dutch randomized trial of interval cytoreductive surgery with or without cisplatin-based HIPEC in stage III disease found longer recurrence-free and overall survival with HIPEC, and the rate of grade 3 or 4 adverse events was similar in both arms (van Driel and colleagues, New England Journal of Medicine). Even so, debate continues about how broadly those results apply.

For pseudomyxoma peritonei, appendiceal cancer and peritoneal mesothelioma, no large randomized trials exist. Treatment here rests on observational series from specialized centers, which can show encouraging outcomes but cannot rule out that selected, fitter patients drive those results. So when you ask "why is HIPEC controversial," a good clinician will answer with your tumor type in mind, not a general verdict.

Is HIPEC surgery worth it? How to weigh the expected benefits

Nobody can answer "is HIPEC surgery worth it" for you in the abstract, and you should be cautious of anyone who tries. What a good consultation can do is translate the evidence for your tumor type into a frank discussion of goals.

Start by asking what the operation is intended to achieve. For some slow-growing appendiceal tumors, the goal of complete cytoreduction is long-term control of disease, and the decision often leans toward surgery when fitness allows. For colorectal peritoneal metastases, the goal is more often extending the time before progression, and the question of whether the heated chemotherapy adds anything to the surgery itself is, as PRODIGE 7 showed, genuinely open. For mesothelioma or ovarian cancer, the framing differs again. Ask your team to name the goal in one sentence, then ask how confident they are and why.

Next, ask for the counterfactual. What would the expected course be with cytoreductive surgery alone, with systemic chemotherapy alone, or with monitoring? Clinicians cannot predict an individual future, but they can describe the range of outcomes seen in people with similar disease, and they can tell you which of those comparisons rest on randomized trials and which on smaller series.

Then weigh the cost in time and function. A recovery measured in weeks to months, a possible stoma, altered bowel habit and months of fatigue are real prices paid up front. For someone whose disease is likely to behave aggressively regardless, those months may matter more than any later gain. For someone with indolent disease and good fitness, the calculation may favor the operation.

Finally, ask how the decision would change if the operation found more disease than expected. A team that has thought this through will have an answer ready.

Questions to ask before HIPEC about a second opinion

A second opinion is not a vote of no confidence in your surgeon. For an uncommon, high-stakes operation whose evidence varies by tumor type, it is simply good practice, and most experienced teams will say so themselves. The National Cancer Institute advises patients to seek a second opinion before major cancer treatment and notes that doctors are generally supportive of the request.

The useful second opinion is a specific one. Ask that your imaging, pathology slides and operative notes from any previous surgery be sent in full, not just the summary letter. Peritoneal disease is notoriously underestimated on CT scans, so a second radiologist’s read can change the estimated disease volume. Pathology review matters too, because the grade of an appendiceal tumor, for example, influences whether HIPEC is reasonable at all.

Questions worth putting to both teams, then comparing:

• How many cytoreductive surgery and HIPEC operations does your team perform each year, and for which tumor types?
• Would you recommend diagnostic laparoscopy before committing to the full operation?
• What completeness of cytoreduction do you expect to achieve, and what makes you think so?
• Would you offer HIPEC for my tumor type given current trial evidence, or surgery alone?
• Is there a clinical trial I could be considered for instead of, or alongside, standard treatment?

If the two opinions disagree, that is information, not a crisis. Ask each team to explain the other’s reasoning as they understand it. Where they converge, you can proceed with more confidence. Where they diverge, you have identified exactly where the uncertainty lies, which is the point of asking in the first place. Your treating team will remain the one making the final recommendation with you.

HIPEC side effects and complications worth asking about

HIPEC side effects come from three sources layered on top of one another: the long operation, the organs removed, and the chemotherapy itself. Separating them helps you ask precise questions.

The surgical risks are those of any major abdominal operation, intensified by its length. Bleeding, infection of the wound or deep inside the abdomen, and blood clots in the legs or lungs are the headline concerns. Where bowel has been joined back together, an anastomotic leak, meaning the join fails and intestinal contents escape, is the complication surgeons most want to avoid, because it often requires a return to the operating room. Prolonged ileus, a temporary paralysis of the gut that delays eating, is common after extensive peritoneal stripping.

The chemotherapy adds its own effects even though exposure to the rest of the body is reduced. Depending on the generic agent used, teams watch for a temporary drop in white blood cells (neutropenia), kidney strain, and in some protocols a transient rise in blood sugar or electrolyte changes. Ask which agent your team uses for your tumor type and which organ it tends to stress.

The numbers matter here, and they should be quoted from evidence rather than reassurance. In PRODIGE 7, serious complications within 60 days occurred in 26% of people who received HIPEC after complete cytoreduction versus 15% who had surgery alone. In the ovarian cancer trial, grade 3 or 4 adverse events were similar with or without HIPEC, around a quarter of each group. The 2003 Dutch colorectal trial reported treatment-related mortality of 8%, a figure that most high-volume teams now describe as lower in their own series, though you should ask for your team’s actual figures rather than assume.

Longer-term effects include altered bowel habit, adhesions that can cause intermittent obstruction, and, where reproductive organs or the spleen were removed, consequences for fertility and infection risk that deserve their own conversation.

Alternatives to HIPEC and how they compare

Any surgeon proposing HIPEC should be able to lay out the alternatives in neutral terms. None of them is universally better; each fits a different combination of tumor type, disease volume and fitness. The table below summarizes the options most often discussed.

Approach	What it involves	Main aim	Usually considered when
Cytoreductive surgery plus HIPEC	Removal of all visible peritoneal disease followed by heated chemotherapy in the abdomen	Control of peritoneal disease, including microscopic residue	Disease confined to the abdomen, complete removal realistic, fitness adequate
Cytoreductive surgery alone	The same resection without the heated perfusion	Removal of visible disease	Tumor types where trials have not shown added benefit from HIPEC, such as colorectal cancer after PRODIGE 7
Systemic chemotherapy or targeted therapy	Drugs given intravenously or by mouth that circulate through the whole body	Slowing disease everywhere, including outside the abdomen	Disease beyond the peritoneum, too much disease to remove, or as a first step to assess response
Active monitoring	Scheduled imaging and review without immediate intervention	Avoiding treatment burden while disease is stable	Very slow-growing tumors, or when fitness needs to improve first
Symptom-directed care	Treating pain, fluid buildup, nausea and bowel problems without aiming to remove disease	Comfort and function	When disease control treatments are unlikely to help or are not wanted

Two of these deserve a note. Systemic therapy and HIPEC are not either-or; many people receive chemotherapy before surgery, after it, or both, and the National Cancer Institute describes these sequences as standard tools rather than fallbacks. And symptom-directed care is not surrender. Palliative care teams often work alongside surgical teams from the outset, and involving them early tends to improve how people feel during treatment of any kind.

Ask your team which rows apply to you, which they would rule out and why, and whether a clinical trial could offer a sixth option.

How to prepare in the weeks before surgery

Once a date is set, the weeks before it are not dead time. Surgical teams increasingly use the term prehabilitation, meaning a structured effort to improve fitness, nutrition and mental readiness before an operation, and for a procedure as demanding as cytoreductive surgery with HIPEC, that effort is worth taking seriously.

Movement comes first. Walking most days, building up gradually, improves the heart and lung reserve you will draw on during a long anesthetic and a slow return to activity afterward. If you have been unwell and lost muscle, ask whether a physiotherapist can set a realistic program. The aim is not athletic performance; it is arriving at surgery slightly stronger than you are today.

Nutrition is the second pillar. Peritoneal disease frequently causes early fullness, bloating and weight loss, which means many people arrive at surgery already depleted. A dietitian can assess whether you need supplements, and your team may check blood markers of nutrition. Tell them honestly how much you are managing to eat.

Medicines need a review. Blood thinners, some diabetes drugs, herbal supplements and certain heart medicines often require adjustment around surgery. Do not stop or change anything yourself; bring a complete list, including over-the-counter products, and let the anesthesia team decide. If you smoke, ask for support to stop; even a few weeks of abstinence helps wound healing and lung recovery.

Practical planning matters too. Arrange who will be at home with you for the first weeks, how you will manage stairs, and who will attend appointments. If a stoma is possible, ask to meet a stoma nurse beforehand so the first time you see one is not the day after surgery. And write your questions down. Long consultations compress quickly in memory, and a notebook does not.

How long does it take to recover from HIPEC?

The question "how long does it take to recover from HIPEC" has two answers: the hospital phase and the home phase, and the second is longer than most people expect.

The first night, and often the first day or two, is usually spent in an intensive care or high-dependency unit so that fluid balance, kidney function and pain can be managed closely. Extensive peritoneal stripping causes large fluid shifts, and the chemotherapy may affect kidney function in the short term, so blood tests are frequent. Most people wake with a urinary catheter, abdominal drains, and a pain-relief system that may include an epidural.

The gut is slow to restart. Ileus is routine after this operation, so eating is reintroduced in stages over several days, beginning with sips and clear fluids. Walking begins early, usually within the first day or two, because mobility reduces clot risk and helps the bowel wake up. The Cleveland Clinic describes a hospital stay that commonly runs around one to two weeks, longer if complications such as infection or a leak arise.

At home, the dominant symptom is fatigue, and it lasts. Energy typically returns over weeks to a few months rather than days, and it is normal to need a rest after short periods of activity well into that window. Appetite recovers gradually; small frequent meals usually work better than three large ones. Bowel habit may be looser or less predictable for a while, especially if part of the colon was removed.

Return to work depends on the job and on how the surgery went, and your team can give a realistic range once they know your operative findings. The honest framing is that HIPEC recovery time is measured in months to feel fully yourself, even when the hospital stay itself is uncomplicated.

Questions to ask before HIPEC about the recovery plan

Recovery goes better when the plan is explicit before the operation rather than improvised at discharge. These are the questions to ask before HIPEC that most often get skipped in the rush to decide about the surgery itself.

Who is my point of contact after discharge, and how do I reach them at night or on a weekend? A named nurse specialist or a direct line to the surgical team changes how safe the first weeks feel. Ask whether there is a written list of problems that should prompt a call, and whether the team wants to hear about low-grade concerns early rather than late.

What will my wound care involve? A long midline incision needs daily inspection for redness, swelling or discharge, and MedlinePlus has clear general guidance on caring for a surgical wound at home. If a stoma is placed, ask when stoma nursing visits will happen and who supplies the equipment.

How will pain be managed at home, and for how long is that expected? Ask about the plan for stepping down pain relief and who prescribes it, without asking for specifics you would apply yourself; those decisions belong to the prescribing clinician.

What about eating? A dietitian follow-up is valuable because weight loss can continue for weeks after this operation. Ask what warning signs of poor nutrition the team wants reported.

When is the first follow-up appointment, and what will be reviewed: wound, blood counts, kidney function, pathology results, and the completeness score achieved? Will further chemotherapy be considered, and when would that conversation happen? Who handles follow-up imaging and at what intervals?

Finally, ask what rehabilitation support exists. Fatigue and deconditioning respond to structured, gradual exercise, and a referral arranged before surgery is easier than one chased afterward.

What people often get wrong about HIPEC

Because HIPEC is unfamiliar, it attracts a set of misunderstandings that shape expectations before anyone has spoken to a surgeon. Correcting them early makes the real conversation more productive.

The first myth is that HIPEC is the treatment. In reality it is a one- to two-hour addition to an operation that may last most of a day, and the evidence from PRODIGE 7 suggests that for colorectal cancer, the surgery does the heavy lifting. If a consultation focuses on the heated chemotherapy and skims over how complete the resection is likely to be, redirect it.

The second is that HIPEC is a last resort offered when nothing else works. The opposite is closer to the truth: it is generally reserved for people whose disease is limited enough, and whose fitness is good enough, to make complete removal realistic. Being told you are not a candidate often reflects disease extent or fitness, not that other options are exhausted.

The third is that the heated chemo "sterilizes" the abdomen. It penetrates only a few millimeters. It cannot compensate for visible deposits left behind, and it does not treat disease elsewhere in the body.

The fourth is that because the chemotherapy stays in the abdomen, there are no systemic side effects. Exposure is reduced, not eliminated. Kidney effects and drops in blood counts occur with some agents and are monitored for that reason.

The fifth is that recovery resembles that from other abdominal surgery. It is longer, and fatigue in particular outlasts the wound.

The last is that the evidence is settled, in either direction. It is strong for some situations, contested for others, and absent in the form of randomized trials for several of the diseases most often treated this way. A clinician who acknowledges that is being accurate, not evasive.

Questions to ask your care team: a list to bring with you

Take this list into the consultation, cross off what has already been answered, and leave space for what comes up. There is no need to ask every item; choose those that matter most to you and let your team guide the rest.

About the diagnosis and the evidence:

• What exactly is my tumor type and grade, and how does that affect whether HIPEC is reasonable?
• Which trials or series support HIPEC for my situation, and which argue against it?
• Would you consider cytoreductive surgery without HIPEC, and why or why not?

About the operation:

• What completeness of cytoreduction do you expect, and will you check with a laparoscopy first?
• Which organs might be removed, and how likely is a stoma, temporary or permanent?
• What will you do if you find more disease than expected once the abdomen is open?
• Which chemotherapy agent will be used, and which organ does it tend to stress?

About risk:

• What are your team’s own complication and reoperation rates for this operation?
• Which complications are most likely in my case, given my health?

About recovery and after:

• How long do you expect me to be in hospital, and what would extend that?
• Who do I call after discharge, and when is the first follow-up?
• Will chemotherapy be considered afterward, and when would that be decided?
• How will fertility, bowel function or infection risk be affected by what is removed?

About the bigger picture:

• What would you expect to happen if I chose a different option, or waited?
• Is there a clinical trial I should know about?
• Would you support a second opinion, and can you send my full records?

Write the answers down, or bring someone who will. The decision remains yours and your team’s together, and it is easier to own a decision you can reconstruct afterward.

When to call your doctor

After cytoreductive surgery with HIPEC, your team will give you specific instructions, and those override anything general. The guidance below describes the kinds of problems that should prompt a same-day call, and a few that should take you straight to emergency care.

Call your surgical team the same day if you notice a fever or shaking chills, since infection inside the abdomen or in the wound can develop in the first weeks and is far easier to treat early. The same applies to a wound that becomes increasingly red, hot, swollen or begins leaking fluid or pus, or to an edge that appears to be opening. Persistent vomiting, inability to keep fluids down, or a belly that becomes newly swollen and tight can signal ileus or bowel obstruction. No stoma output for many hours alongside bloating, or a stoma that turns dark or dusky, needs urgent review. New or worsening abdominal pain that is not controlled by your prescribed plan is worth a call rather than waiting for the next appointment, as is passing very little urine for most of a day, which can indicate dehydration or kidney strain after the chemotherapy.

Seek emergency care without waiting if you develop sudden chest pain, sudden breathlessness, or a swollen, painful calf, because blood clots in the legs and lungs are a recognized risk after long abdominal operations. Heavy bleeding from the wound, fainting, a racing heart with lightheadedness, or confusion are also emergencies.

Between those extremes, a good rule is that your team would rather hear from you about a small worry than learn about a large one late. Keep the contact numbers somewhere visible, and if you are unsure whether something counts, call anyway. The decision about what to do next always sits with the clinicians who know your operation.

Frequently asked questions

When is HIPEC not recommended?

HIPEC is usually not recommended when cancer has spread beyond the abdominal cavity to the liver interior, lungs or bones, when the small bowel is so extensively involved that complete removal would leave too little intestine, or when heart, lung or kidney disease makes a long operation unsafe. Teams may also decline it for fast-growing tumor types, or for colorectal cancer where trial evidence has not shown benefit over surgery alone.

How long does it take to recover from HIPEC?

Hospital recovery commonly takes around one to two weeks, including an initial period in intensive or high-dependency care, with longer stays if complications occur. At home, fatigue usually persists for weeks to a few months, appetite returns gradually, and bowel habit may be altered for a while. Your team can give a more personal estimate once they know what was removed and how the operation went.

Why is HIPEC controversial?

The evidence varies sharply by cancer type. For colorectal peritoneal metastases, the PRODIGE 7 trial found that adding HIPEC to complete surgery did not improve survival and increased serious complications. For stage III ovarian cancer, a randomized trial found benefit. For appendiceal tumors and mesothelioma, there are no large randomized trials at all. Clinicians therefore disagree about where the procedure belongs, and the debate is specific rather than general.

Is HIPEC surgery worth it?

That depends on your tumor type, how much disease is present, your fitness and your goals, so it cannot be answered in the abstract. Ask your team to name the aim of the operation in one sentence, to describe the likely course with the alternatives, and to say which of those comparisons rest on randomized trials. Weigh that against a recovery measured in months and the possibility of a stoma.

What are the most common HIPEC side effects?

The most common problems are those of major abdominal surgery: fatigue, temporary bowel paralysis that delays eating, wound or deep infection, bleeding, and blood clots. Where bowel has been rejoined, a leak at the join is the complication surgeons most want to prevent. The chemotherapy can also cause a temporary drop in white cells or strain on the kidneys, depending on the generic agent used, which is why blood tests are frequent afterward.

What is HIPEC recovery time at home like week by week?

The first weeks at home are dominated by tiredness, a small appetite and a healing wound that needs daily inspection. Walking short distances several times a day is encouraged from the start. Over the following weeks energy gradually returns, meals become larger and bowel habit settles, though full recovery often takes a few months. Your team will set the pace for lifting, driving and returning to work.

Should I get a second opinion before HIPEC?

Yes, for an uncommon operation with evidence that differs by tumor type, a second opinion is sensible and most experienced teams encourage it. Ask that your full imaging, pathology slides and previous operative notes be sent, not just a summary. A second radiology or pathology review can change the estimated disease extent or tumor grade, which in turn can change whether HIPEC is recommended at all.

What is cytoreductive surgery, and is it the same as HIPEC?

Cytoreductive surgery is the operation that removes all visible tumor from the peritoneum and any involved organs; HIPEC is the heated chemotherapy wash that may follow it in the same operation. They are not the same. Many teams now offer cytoreductive surgery without HIPEC for colorectal cancer, following trial results, while still combining the two for other tumor types. Ask which your team is proposing and why.

Will I need a stoma after HIPEC?

Not everyone does, but it is a real possibility whenever part of the bowel is removed, particularly the rectum or lower colon. Some stomas are temporary and reversed months later once healing is complete; others are permanent. Ask your surgeon for the realistic likelihood in your case before the operation, and request a meeting with a stoma nurse beforehand so the first encounter is not after surgery.

Can I have chemotherapy before or after HIPEC as well?

Yes, systemic chemotherapy is often given before cytoreductive surgery to assess how the disease responds, after it to address microscopic disease elsewhere, or both. These are standard sequences rather than fallbacks. Whether and when you receive it depends on your tumor type, the completeness of the operation and the final pathology, and that decision rests with your oncology and surgical teams together.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.